Views & Analysis | Perspectives on pharma industry issues

R&D

Changing Faces: Pharma and biotech hires, June & July 2026

In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

Patients

Longevity as the new health paradigm: The control system

Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Virtual trials and the next generation of pharma clinical re...

Previously viewed as a ‘nice to have’ for the pharma industry, virtual trials were already moving from a theoretical to a practical proposition before COVID-19 accelerated their transition.

Views & Analysis

2021 market access prospects for Italy

Italy was working up big changes in market access throughout 2020 which will be implemented in 2021.

Views & Analysis

COVID drives a customer experience shift in life sciences CR...

The future of life sciences CRM will be defined by rapid digital transformation and a focus on customer experience – and those who stick to old ways of working will be left in the dust, acc

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Oncology

Sponsored

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Patients

Longevity as the new health paradigm: The control system

Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed

Patients

Sponsored

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Changing Faces: Pharma and biotech hires, June & July 2026

Personalisation is the biggest lie brands keep telling

Australia, AI, and Autolomous

GLP-1 RAs in CKM management: A Q&A with CORXEL

Longevity as the new health paradigm: The control system

Virtual trials and the next generation of pharma clinical re...

2021 market access prospects for Italy

COVID drives a customer experience shift in life sciences CR...

Personalisation is the biggest lie brands keep telling

M&A trends in diagnostics and life sciences tools

Australia, AI, and Autolomous

Smaller, smarter devices for global trial diversity

Europe’s new HTA reality: The JCA, one year on

Why global pharmaceutical reforms are quietly redirecting ra...

Key lessons from EHA 2026: Translating evidence into impact

Establishing ctDNA as a validated primary surrogate endpoint

Early diagnosis means little without timely treatment

Longevity as the new health paradigm: The control system

12 Questions with Kim Innes

Why Britain's blood tests are only as reliable as the journe...

Changing Faces: Pharma and biotech hires, June & July 2026

GLP-1 RAs in CKM management: A Q&A with CORXEL

Clinical Trials Round-Up: May and June 2026

Skylark trials gene therapy for common form of child deafnes...

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks